Forty-Eight US FDA Drug Application Decisions Delayed By Pandemic's Deferred Inspections
US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up.
You may also be interested in...
Final commitment letter preparations now under way as revenue issues are resolved.
CDER would receive $17m less in Senate appropriations bill compared to House veion, while CFSAN's total would be nearly $10m less. Overall, Senate bill includes around $50.4m less in funding for FDA than House bill.
CDER would lose the most money in the Senate appropriations bill compared to the House version, while CBER would see an increase.